Equity Research & Views

Riding a power-grid boom, winning big transformer orders including for US data centres, with capacity being multiplied several-fold and a new semiconductor bet. Cleaned-up, debt-free business; current management consistently delivers, though the turnaround is young.

Grid-equipment maker in India's massive power build-out; orders booked equal ~3 years of sales and profit margins tripled. Management reliably under-promises and over-delivers. Strongest pick here.

Carbon maker steadily shifting from cheap grades to costly ones, which more than doubled its margins, and fresh capacity has restarted volume growth after two capped years. Promoters keep raising their stake. The battery-material bet earns nothing until FY28 and takes on China, and it adds a new venture almost every quarter.

Injectable-drug maker whose loss-making Europe unit finally turned profitable, powering profit up 47%. Contract manufacturing is the growth engine, plus future weight-loss-drug upside. But that Europe fix arrived a year late.

Solar panel and cell maker. Made-in-India cells have crossed half of sales now that local-content rules are in force, and that is the higher-margin half; a fully funded plant nearly doubles capacity by March 2027. Management gave its first-ever target this year and still has to prove it, and industry overcapacity is the real risk.

Makes advanced pharma-chemical building blocks (formerly Ami Organics). A shift into high-value CDMO contracts has doubled both margins and profit, and management keeps beating its own guidance. Main worry is the rich price, near record highs.

Makes precision parts for AI-data-centre fuel cells and nuclear reactors. Order book tripled, profit up 76% - real growth. Catch: leans heavily on one US customer and often misses its targets.

Makes generators for gas power plants, with booming demand from AI data centres; order book more than doubled and management keeps beating its own targets. Caveats: very expensive stock and founders selling down heavily.

Makes precision-forged auto parts and is fast building an aerospace, defence and semiconductor arm - sales there jumped 155% to Rs 315 crore, lifting profit and margins. But the stock is priced very richly.

Shifted from raw ingredients to finished tablets, lifting margins and finally breaking three flat years (sales +20%). Swiss weight-loss-drug arm now profitable. Watch: a US FDA plant issue stays unresolved.

India's largest children's-hospital chain. It has built lots of new beds that are still half-empty, so profits can grow just by filling them. New CEO targets 20% growth; management delivers consistently.

Transformer maker in India's power-grid boom. Order book is at a record 1.5 years of sales, the high-voltage orders it long promised are finally landing, and its big new plant is only about a third full so there is plenty of room to grow. Management delivers, but the stock is expensive.

Steady branded-medicine maker growing twice as fast as the market, and it beat its own targets. New brands, weight-loss drug launch and fertility push add fresh growth; management delivers.

Buys and builds hospitals at half the usual cost, then fills the beds. Profit up 27%, now debt-free, and future expansion is fully self-funded. A third of beds still empty means room to grow.

Merging two drug firms nearly tripled profit margins and grew profit 14-fold - management delivered early and honestly. A real, proven turnaround; only catch is the pricey stock.

Pharma turnaround finally paying off: profit doubled, debt slashed, new drug launched. But management repeatedly hypes then quietly drops promised drug deals, and a US FDA warning stays unresolved.

Makes compressors India used to import, winning market share with record orders and its best-ever profit margins. A real growth engine - but it keeps missing its own sales-growth targets.

Only large Indian maker of solar-panel glass, and import duties now locked in to 2029 have transformed its margins. A fully funded expansion lifts capacity 60% by March 2027, and the loss-making German unit is written off and gone. A long furnace shutdown falls due around FY28.

Engineering firm with a huge confirmed order book riding India's infra boom. Red flag: the flashy '4x growth' was only on paper, and a group merger dilutes owners ~26%. Very expensive stock.

Low-cost maker of a key stainless-steel ingredient. Nearly doubling output via a bought Tata plant plus a new one, right as global prices spike. Genuine growth, reasonably priced; watch for delays.

A proven engine: buy hospitals cheaply near Delhi, fill beds, raise the bill per bed. Sales up 36%, heading to 5,000 beds. New premium Gurugram hospital opens 2027; management delivers.

India's biggest transformer-wire maker, growing steadily on the grid boom (sales +35%, profit +72%). New copper plant should lift margins, but it's not running yet and stock is pricey.

India's biggest maker of upgraded high-performance plastics for cars and appliances. A fully-funded new-plant expansion is live, profit margins keep rising yearly, almost no debt, and management delivers what it promises.

Debt-free drug-ingredient maker winning business as the world shifts away from China. Rich, rising margins; management consistently delivers. New capacity funded, breaking ground next year.